This afternoon's earnings results will only be window-dressing for what's coming ahead. Buying Intel stock is about next year and beyond.
What kind of company will Yahoo! be? The clock is running.
Investors are faced with the decision of when to cash out. It's a problem market participants everywhere wish they had.
Yum! has a strong global reach and more pricing power than Chipotle. But what about that menu?
Upon completion of this deal, AbbVie's stock should head toward the $70 level in the next 12 to 18 months, representing gains of close to 30%.
On the basis of improved/discounted earnings and cash flow growth, the stock will have to trade at its rightful fair market value of around $70.
'Bigger' only for the sake of getting bigger makes no sense. Not trusting management of the company to execute the business is the worst blunder of them all.
Investors have already paid once for Citi's mistake, missing out on a good buying opportunity would be another.
Regardless of what period or decade you research, there is plenty of evidence showing active pickers consistently underperform the S&P 500.
This deal, when completed, will boost Abbvie shares to $70 in the next 12 months from the current $55.